ArticleTherapeutic advances in neurological disorders2012
Current and emerging therapies in multiple sclerosis: a systematic review.
Article in Therapeutic advances in neurological disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- A Systematic Review of Discrete-Choice Experiments and Conjoint Analysis Studies in People with Multiple Sclerosis.The patient · 2018Pooled it
- Pooled it
- A pilot study to improve adherence among MS patients who discontinue treatment against medical advice.Journal of behavioral medicine · 2016Trial
- Randomized study combining interferon and glatiramer acetate in multiple sclerosis.Annals of neurology · 2013Trial
- A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States: PREG-MS.Neurology. Clinical practice · 2025Article
- Fingolimod potentiates the antifungal activity of fluconazole against fluconazole-resistantFrontiers in cellular and infection microbiology · 2025Article
- Fingolimod Inhibits Exopolysaccharide Production and Regulates Relevant Genes to Eliminate the Biofilm ofInternational journal of molecular sciences · 2024Article
- Molecular Hydrogen: an Emerging Therapeutic Medical Gas for Brain Disorders.Molecular neurobiology · 2023Review
- Higher throughput workflow with sensitive, reliable and automatic quantification of myelination in vitro suitable for drug screening.Scientific reports · 2023Article
- RETRACTED: Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses.Current issues in molecular biology · 2022Article
- Fingolimod Promotes Antibacterial Effect of Doripenem against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Delayed Maturation of Oligodendrocyte Progenitors by Microgravity: Implications for Multiple Sclerosis and Space Flight.Life (Basel, Switzerland) · 2022Article
- Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah, Saudi Arabia.Neurosciences (Riyadh, Saudi Arabia) · 2022Observational
- A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.Frontiers in neurology · 2022Review
- Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients.Journal of personalized medicine · 2021Review
- Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.Frontiers in immunology · 2021Review
- Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.Neurology research international · 2021Article
- The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.The patient · 2020Article
- The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review.Current journal of neurology · 2020Article
- Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β).ACS omega · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.